Tobramycin PF (Pfizer (Perth))

What it is used for

INDICATIONS AS AT 01 MARCH 2001 : For the treatment of serious infections of the following type where they are caused by susceptible organisms: Skin and skin structure infections including burns, bone infections; gastrointestinal infections including peritonitis; central nervous system infections including meningitis, septicaemia and neonatal sepsis; lower respiratory tract infections including pneumonia, bronchopneumonia, and acute bronchitis; complicated and recurrent urinary tract infections such as pyelonephritis and cystitis. Aminoglycosides, including tobramycin, should not be used in uncomplicated initial episodes of urinary tract infection unless the causative organisms are not susceptible to other less toxic antibiotics. Tobramycin can be used in serious staphylococcal infections for which penicillin or other less toxic drugs are contraindicated and where susceptibility testing and clinical judgement indicate its use. If susceptibility tests show a resistance to tobramycin in the causative organisms other appropriate therapy should be instituted. Prior to and during therapy with tobramycin, bacterial cultures should be taken to isolate and identify causative organisms and to test their susceptibility to tobramycin. The decision to continue tobramycin therapy depends on the susceptibility of causative organisms, severity of infection and risk of toxicity. When Gram-negative septicaemia, neonatal sepsis, or meningitis is present, tobramycin therapy may be begun prior to the results of the susceptibility tests. The same applies even if the patient is receiving concurrent therapy of a penicillin or cephalosporin with an aminoglycoside.